Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2014
06/24/2014US8758760 Oral vaccine
06/24/2014US8758759 Transmucosal administration of aggregated antigens
06/24/2014US8758758 Post-relapse treatment of CD30 expressing lymphomas
06/24/2014US8758757 Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
06/24/2014US8758756 Anti-human epidermal growth factor receptor antibody and uses thereof
06/24/2014US8758755 Stem cell fusion model of carcinogenesis
06/24/2014US8758754 Nogo-A binding molecules and pharmaceutical use thereof
06/24/2014US8758753 Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors
06/24/2014US8758752 RS7 antibodies
06/24/2014US8758750 Synergistic anti-CD47 therapy for hematologic cancers
06/24/2014US8758749 Biological materials and uses thereof
06/24/2014US8758748 Anti-angiogenic therapy
06/24/2014US8758747 Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
06/19/2014WO2014093950A1 Immune modulator for immunotherapy and vaccine formulation
06/19/2014WO2014093897A1 Wt1 vaccine
06/19/2014WO2014093894A2 Dna antibody constructs and method of using same
06/19/2014WO2014093886A1 Wt1 vaccine
06/19/2014WO2014093870A2 Use of c-c chemokine receptor type 7 (ccr7) inhibitors
06/19/2014WO2014093855A1 Target peptides for ovarian cancer therapy and diagnostics
06/19/2014WO2014093786A1 Methods for increasing the efficiency of hybridoma generation
06/19/2014WO2014093702A1 Hiv therapeutics and methods of making and using same
06/19/2014WO2014093671A1 Compositions and methods for capture of cellular targets of bioactive agents
06/19/2014WO2014093619A1 Methods and compositions of protein antigens for the diagnosis and treatment of leptospirosis
06/19/2014WO2014093602A1 Compositions and methods for treating and preventing hepatitis c virus infection
06/19/2014WO2014093531A1 Modulation of myofiber repair by anti-myostatin in strategies with stem cells
06/19/2014WO2014093417A1 Compositions and methods for regulating erythropoiesis
06/19/2014WO2014093270A1 Tropism modified cancer terminator virus (ad.5/3 ctv;ad.5/3-ctv-m7)
06/19/2014WO2014093206A1 Lyophilized spherical pellets of anti-il-23 antibodies
06/19/2014WO2014093203A1 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
06/19/2014WO2014093182A1 Compositions, methods of administration and uses for trivalent dengue virus formulations
06/19/2014WO2014092858A1 Compositions and methods for treatment of cancer
06/19/2014WO2014092804A1 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
06/19/2014WO2014092528A1 Vaccination adjuvant, and preparation and vaccines containing same
06/19/2014WO2014092378A1 Multivalent pneumococcal polysaccharide-protein conjugate composition
06/19/2014WO2014092377A1 Multivalent pneumococcal polysaccharide-protein conjugate composition
06/19/2014WO2014092227A1 Composition for treatment of diseases related to removal of extracellular alpha-synuclein and method for screening therapeutic agent for said diseases
06/19/2014WO2014091463A1 Method for producing leishmania recombinant proteins and use in a diagnostic kit and vaccine against leishmaniases
06/19/2014WO2014091244A1 Immunogenic compositions for use in aerosol delivery
06/19/2014WO2014090265A1 Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
06/19/2014WO2014090053A1 Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial cell growth factor and its receptor, and coding sequence and use thereof
06/19/2014WO2014065679A4 Lyme disease vaccine
06/19/2014WO2014063704A3 M. tuberculosis vaccines
06/19/2014WO2014055413A3 A method of providing cellular therapy using modified natural killer cells or t lymphocytes
06/19/2014WO2014045022A3 Agents and methods
06/19/2014WO2013166448A8 Stable formulations containing anti-pcsk9 antibodies
06/19/2014WO2013068563A9 Antibody molecules having specificity for human ox40
06/19/2014WO2013006842A3 Self-replicating rna prime - protein boost vaccines
06/19/2014US20140170225 Immunotherapy for treatment of amyloid-related disorders using encapsulated beta-amyloid peptides
06/19/2014US20140170190 Attenuated Mannheimia haemolytica Vaccines and Methods of Making and Use
06/19/2014US20140170189 Bacterial Ribonucleic Acid Cell Wall Compositions and Methods of Making and Using Them
06/19/2014US20140170188 BACILLUS ANTHRACIS HtrA-DEFECTIVE-DERIVED VACCINES
06/19/2014US20140170187 Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
06/19/2014US20140170185 Emulsion containing a non-live medicinal substance
06/19/2014US20140170181 Vaccine against white spot syndrome virus
06/19/2014US20140170180 Porcine parvovirus 5a, methods of use and vaccine
06/19/2014US20140170179 P16ink4a derived peptides for prophylaxis and therapy of hpv-associated tumors and other p16ink4a expressing tumors
06/19/2014US20140170178 Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
06/19/2014US20140170175 Novel lipids and compositions for intracellular delivery of biologically active compounds
06/19/2014US20140170174 Polychlorinated biphenyls and squalene-containing adjuvants
06/19/2014US20140170172 Tat-Based Tolerogen Compositions and Methods for Making and Using Same
06/19/2014US20140170169 Blocking antibody for transplantation
06/19/2014US20140170165 Methods of generating hyper inos expressing cells and uses thereof
06/19/2014US20140170162 Preservation of the neuromuscular junction (nmj) after traumatic nerve injury
06/19/2014US20140170160 Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
06/19/2014US20140170158 Compositions and methods for treating or preventing lung diseases
06/19/2014US20140170156 Human monoclonal antibodies against interleukin 8 (il-8)
06/19/2014US20140170155 Method for Treating a GD2 Positive Cancer
06/19/2014US20140170152 Immunobinders directed against tnf
06/19/2014US20140170150 N-linked glycan compounds
06/19/2014US20140170149 Bispecific antibodies against her2 and cd3
06/19/2014US20140170148 Bispecific antibodies against her2
06/19/2014US20140170147 Compositions and methods of use for antibodies of dickkopf-1
06/19/2014US20140170143 Use of an anti-cd200 antibody for prolonging the survival of allografts
06/19/2014US20140170142 Molecules With Extended Half-Lives And Uses Thereof
06/19/2014US20140170141 Polypeptides and uses thereof for treatment of autoimmune disorders and infection
06/19/2014US20140170140 Compositions and methods for the treatment of neuromyelitis optica
06/19/2014US20140170135 Egfr expression is associated with decreased benefit from trastuzumab in the ncctg n9831 trial
06/19/2014US20140170134 Compositions and methods related to antibodies to staphylococcal protein a
06/19/2014US20140170112 Compositions for ameliorating systemic inflammation and methods for making and using them
06/19/2014US20140170063 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity
06/18/2014EP2742953A1 Therapeutic agent for autoimmune diseases comprising pd-1 agonist
06/18/2014EP2742952A1 Influenza vaccine composition
06/18/2014EP2742951A2 Strain independent amplification of HIV polynucleotides
06/18/2014EP2742361A1 Angiopoietin-like 4 and its use in modulating cell leakiness
06/18/2014EP2742139A1 Immunogenic compositions and methods therefor
06/18/2014EP2742068A1 New antibodies against phosphorylcholine
06/18/2014EP2742067A2 Anti-fzd10 monoclonal antibodies and methods for their use
06/18/2014EP2741785A2 Novel clostridium difficile dna vaccine
06/18/2014EP2741774A2 Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow
06/18/2014EP2741773A1 Methods of treating progressive forms of multiple sclerosis
06/18/2014EP2741772A1 Pasteurellaceae vaccines
06/18/2014EP2741771A2 Methods and compositions for the treatment of autoimmune and inflammatory diseases
06/18/2014EP2741770A1 Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
06/18/2014EP2741769A2 Highly galactosylated antibodies
06/18/2014EP2741768A2 Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
06/18/2014CN103874709A Anti-tie2 antibodies uses thereof
06/18/2014CN103874707A Neutralizing anti-CCL20 antibodies
06/18/2014CN103874510A Use of the PACAP as a molecular adjuvant for vaccines
06/18/2014CN103874509A Hypoallergenic variants of mal d 1, the major allergen from malus domestica
06/18/2014CN103874508A Recombinant nonpathogenic MDV vector providing multivalent immunity
1 ... 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 ... 1823